Table 4.

Concordance between self‐collected vaginal and clinician‐collected cervical samples using manufacturer's cut‐offs.

	HPV type	+/+	+/−	−/+	−/−	Agreement [%]	Kappa [95% CI]
Total population (n  = 449)	hrHPV	241	15	29	164	90.2	0.798 (0.742–0.855)
	HPV16	60	7	10	372	96.2	0.854 (0.786–0.921)
	HPV18	13	2	4	430	98.7	0.806 (0.654–0.957)
	Other hrHPV	185	13	38	213	88.6	0.773 (0.714–0.831)
≥ CIN2 (n  = 110)	hrHPV	90	6	2	12	92.7	0.708 (0.519–0.897)
	HPV16	34	4	5	67	91.8	0.820 (0.708–0.933)
	HPV18	3	1	0	106	99.1	0.853 (0.568–1.000)
	Other hrHPV	64	4	5	37	91.8	0.826 (0.717–0.935)
< CIN2 (n  = 339)	hrHPV	151	9	27	152	89.4	0.788 (0.723–0.853)
	HPV16	26	3	5	305	97.7	0.854 (0.754–0.953)
	HPV18	10	1	4	324	98.5	0.792 (0.616–0.969)
	Other hrHPV	121	9	33	176	87.6	0.747 (0.677–0.818)

Note: Color legend: for the concordance: dark green (1.00 ≥ K > 0.80): excellent; light green (0.80 ≥ K > 0.60): good; yellow (0.60 ≥ K > 0.40): moderate; orange (0.40 ≥ K > 0.20): fair; red (0.20 ≥ K > 0.00): poor. +/+ positive on vaginal and cervical samples, +/− positive only on cervical samples, −/+ positive only on vaginal samples, −/− negative on both sample types. Manufacturer's positivity threshold for all hrHPV types in cervical samples and vaginal self‐samples Ct ≤ 40.

Abbreviations: 95% CI, 95% confidence interval; CIN, cervical intraepithelial neoplasia; N, number.